LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article: Molecular Properties and Therapeutic Targeting of the EBV-Encoded Receptor BILF1.

    Knerr, Julius Maximilian / Kledal, Thomas Nitschke / Rosenkilde, Mette Marie

    Cancers

    2021  Volume 13, Issue 16

    Abstract: The γ-herpesvirus Epstein-Barr Virus (EBV) establishes lifelong infections in approximately 90% of adults worldwide. Up to 1,000,000 people yearly are estimated to suffer from health conditions attributed to the infection with this virus, such as ... ...

    Abstract The γ-herpesvirus Epstein-Barr Virus (EBV) establishes lifelong infections in approximately 90% of adults worldwide. Up to 1,000,000 people yearly are estimated to suffer from health conditions attributed to the infection with this virus, such as nasopharyngeal and gastric carcinomas as well as several forms of B, T and NK cell lymphoma. To date, no EBV-specific therapeutic option has reached the market, greatly reducing the survival prognoses of affected patients. Similar to other herpesviruses, EBV encodes for a G protein-coupled receptor (GPCR), BILF1, affecting a multitude of cellular signaling pathways. BILF1 has been identified to promote immune evasion and tumorigenesis, effectively ensuring a life-long persistence of EBV in, and driving detrimental health conditions to its host. This review summarizes the epidemiology of EBV-associated malignancies, their current standard-of-care, EBV-specific therapeutics in development, GPCRs and their druggability, and most importantly consolidates the findings of over 15 years of research on BILF1 in the context of EBV-specific drug development. Taken together, BILF1 constitutes a promising target for the development of novel EBV-specific therapeutics.
    Language English
    Publishing date 2021-08-13
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers13164079
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Reply to: How Many SARS-CoV-2 "Viroporins" Are Really Ion Channels?

    Toft-Bertelsen, Trine L / Jeppesen, Mads Gravers / Landbrug, Asante / Mujezinovic, Amer / Bentzen, Bo Hjorth / Kledal, Thomas Nitschke / Rosenkilde, Mette Marie

    Communications biology

    2022  Volume 5, Issue 1, Page(s) 860

    MeSH term(s) COVID-19 ; Humans ; Ion Channels ; SARS-CoV-2 ; Viral Proteins/metabolism ; Viroporin Proteins
    Chemical Substances Ion Channels ; Viral Proteins ; Viroporin Proteins
    Language English
    Publishing date 2022-08-25
    Publishing country England
    Document type Letter ; Comment
    ISSN 2399-3642
    ISSN (online) 2399-3642
    DOI 10.1038/s42003-022-03670-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Publisher Correction: Reply to: How many SARS-CoV-2 "viroporins" are really ion channels?

    Toft-Bertelsen, Trine L / Jeppesen, Mads Gravers / Landbrug, Asante / Mujezinovic, Amer / Bentzen, Bo Hjorth / Kledal, Thomas Nitschke / Rosenkilde, Mette Marie

    Communications biology

    2022  Volume 5, Issue 1, Page(s) 1017

    Language English
    Publishing date 2022-09-27
    Publishing country England
    Document type Published Erratum
    ISSN 2399-3642
    ISSN (online) 2399-3642
    DOI 10.1038/s42003-022-03982-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Amantadine for COVID-19 treatment (ACT) study: a randomized, double-blinded, placebo-controlled clinical trial.

    Weis, Nina / Bollerup, Signe / Sund, Jon Dissing / Glamann, Jakob Borg / Vinten, Caroline / Jensen, Louise Riger / Sejling, Christoffer / Kledal, Thomas Nitschke / Rosenkilde, Mette Marie

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

    2023  Volume 29, Issue 10, Page(s) 1313–1319

    Abstract: Objectives: The COVID-19 pandemic has revealed a severe need for effective antiviral treatment. The objectives of this study were to assess if pre-emptive treatment with amantadine for COVID-19 in non-hospitalized persons ≥40 years or adults with ... ...

    Abstract Objectives: The COVID-19 pandemic has revealed a severe need for effective antiviral treatment. The objectives of this study were to assess if pre-emptive treatment with amantadine for COVID-19 in non-hospitalized persons ≥40 years or adults with comorbidities was able to prevent disease progression and hospitalization. Primary outcomes were clinical status on day 14.
    Methods: Between 9 June 2021 and 27 January 2022, this randomized, double-blinded, placebo-controlled, single-centre clinical trial included 242 subjects with a follow-up period of 90 days. Subjects were randomly assigned 1:1 to either amantadine 100 mg or placebo twice daily for 5 days. The inclusion criteria were confirmed SARS-CoV-2 infection and at least one of (a) age ≥40 years, age ≥18 years and (b) at least one comorbidity, or (c) body mass index ≥30. The study protocol was published at www.
    Clinicaltrials: gov (unique protocol #02032021) and at www.clinicaltrialregister.eu (EudraCT-number 2021-001177-22).
    Results: With 121 participants in each arm, we found no difference in the primary endpoint with 82 participants in the amantadine arm, and 92 participants in the placebo arm with no limitations to activities, respectively, and 25 and 37 with limitations to activities in the amantadine arm and the placebo arm, respectively. No participants in either group were admitted to hospital or died. The OR of having state severity increased by 1 in the amantadine group versus placebo was 1.8 (CI 1.0-3.3, [p 0.051]). On day 7, one participant was hospitalized in each group; throughout the study, this increased to five and three participants for amantadine versus placebo treatment (p 0.72). Similarly, on day 7, there was no difference in the status of oropharyngeal swabs. Most participants (108 in each group) were SARS-CoV-2 RNA positive (p 0.84).
    Conclusion: We found no effect of amantadine on disease progression of SARS-CoV-2 infection.
    MeSH term(s) Adult ; Humans ; Adolescent ; COVID-19 ; SARS-CoV-2 ; Pandemics/prevention & control ; COVID-19 Drug Treatment ; RNA, Viral ; Amantadine/therapeutic use ; Treatment Outcome ; Double-Blind Method
    Chemical Substances RNA, Viral ; Amantadine (BF4C9Z1J53)
    Language English
    Publishing date 2023-06-22
    Publishing country England
    Document type Randomized Controlled Trial ; Journal Article
    ZDB-ID 1328418-6
    ISSN 1469-0691 ; 1470-9465 ; 1198-743X
    ISSN (online) 1469-0691
    ISSN 1470-9465 ; 1198-743X
    DOI 10.1016/j.cmi.2023.06.023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4541: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 284: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Author Correction: Amantadine inhibits known and novel ion channels encoded by SARS-CoV-2 in vitro.

    Toft-Bertelsen, Trine Lisberg / Jeppesen, Mads Gravers / Tzortzini, Eva / Xue, Kai / Giller, Karin / Becker, Stefan / Mujezinovic, Amer / Bentzen, Bo Hjorth / Andreas, Loren B / Kolocouris, Antonios / Kledal, Thomas Nitschke / Rosenkilde, Mette Marie

    Communications biology

    2021  Volume 4, Issue 1, Page(s) 1402

    Language English
    Publishing date 2021-12-10
    Publishing country England
    Document type Published Erratum
    ISSN 2399-3642
    ISSN (online) 2399-3642
    DOI 10.1038/s42003-021-02940-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2.

    Toft-Bertelsen, Trine Lisberg / Jeppesen, Mads Gravers / Tzortzini, Eva / Xue, Kai / Giller, Karin / Becker, Stefan / Mujezinovic, Amer / Bentzen, Bo Hjorth / B Andreas, Loren / Kolocouris, Antonios / Kledal, Thomas Nitschke / Rosenkilde, Mette Marie

    Communications biology

    2021  Volume 4, Issue 1, Page(s) 1347

    Abstract: The dire need for COVID-19 treatments has inspired strategies of repurposing approved drugs. Amantadine has been suggested as a candidate, and cellular as well as clinical studies have indicated beneficial effects of this drug. We demonstrate that ... ...

    Abstract The dire need for COVID-19 treatments has inspired strategies of repurposing approved drugs. Amantadine has been suggested as a candidate, and cellular as well as clinical studies have indicated beneficial effects of this drug. We demonstrate that amantadine and hexamethylene-amiloride (HMA), but not rimantadine, block the ion channel activity of Protein E from SARS-CoV-2, a conserved viroporin among coronaviruses. These findings agree with their binding to Protein E as evaluated by solution NMR and molecular dynamics simulations. Moreover, we identify two novel viroporins of SARS-CoV-2; ORF7b and ORF10, by showing ion channel activity in a X. laevis oocyte expression system. Notably, amantadine also blocks the ion channel activity of ORF10, thereby providing two ion channel targets in SARS-CoV-2 for amantadine treatment in COVID-19 patients. A screen of known viroporin inhibitors on Protein E, ORF7b, ORF10 and Protein 3a from SARS-CoV-2 revealed inhibition of Protein E and ORF7b by emodin and xanthene, the latter also blocking Protein 3a. This illustrates a general potential of well-known ion channel blockers against SARS-CoV-2 and specifically a dual molecular basis for the promising effects of amantadine in COVID-19 treatment. We therefore propose amantadine as a novel, cheap, readily available and effective way to treat COVID-19.
    MeSH term(s) Amantadine/pharmacology ; Amiloride/analogs & derivatives ; Amiloride/pharmacology ; Antiviral Agents/pharmacology ; Ion Channels/physiology ; Rimantadine/pharmacology ; SARS-CoV-2/drug effects ; Viral Proteins/physiology
    Chemical Substances Antiviral Agents ; Ion Channels ; Viral Proteins ; Rimantadine (0T2EF4JQTU) ; 5-(N,N-hexamethylene)amiloride (1428-95-1) ; Amiloride (7DZO8EB0Z3) ; Amantadine (BF4C9Z1J53)
    Language English
    Publishing date 2021-12-01
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2399-3642
    ISSN (online) 2399-3642
    DOI 10.1038/s42003-021-02866-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top